Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | NIVOREN GETUG-AFU 26: Updates and implications

Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, speaking on the NIVOREN GETUG-AFU 26 study: the real-world implications of nivolumab in metastatic renal cell carcinoma patients. This interview was recorded at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.